Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Related Experimental Eli Lilly weight loss drug proves promising ... U.S. News // 10 hours ago Secret Service agents arrest man who scaled wall at Mar-a-Lago June 4 (UPI) -- A 23-year-old Texas ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Eli Lilly already posted preliminary data showing its obesity drug, Zepbound topped Novo Nordisk’s Wegovy on measures of weight loss in a head-to-head clinical trial. More detailed results ...